# Elite Peps Australia

> Evidence-based peptide science, clinical trials, biotechnology and Australian regulation.


## Posts

- [Weight Regain After Stopping GLP-1 Medicines: What Trials Show](https://elitepepsaustralia.com/weight-regain-after-stopping-glp-1-trials/): Compare STEP 1, STEP 4 and SURMOUNT-4 withdrawal findings, their study timelines and weight-change denominators, and limits on predicting individual regain.
- [Semaglutide and Kidney Disease: What the FLOW Trial Shows](https://elitepepsaustralia.com/semaglutide-kidney-disease-flow-trial-australia/): FLOW tested semaglutide in 3,533 adults with type 2 diabetes and chronic kidney disease. Read the kidney outcomes, evidence limits and Australian TGA status.
- [CagriSema Trial Results: What REDEFINE 1 and REDEFINE 2 Actually Show](https://elitepepsaustralia.com/cagrisema-redefine-1-redefine-2-trial-results/): CagriSema combines cagrilintide and semaglutide. Read the phase 3 REDEFINE 1 and 2 results, analysis methods, safety findings and evidence limits.
- [MASH and MASLD Drug Evidence: FDA Decisions and Trial Tracker](https://elitepepsaustralia.com/mash-masld-drug-trial-evidence-tracker/): Track MASH drug evidence across FDA decisions and primary trials, with biopsy endpoints, analysis populations and confirmatory-outcome limits kept separate.
- [Amylin vs GLP-1: CagriSema and Emerging Obesity Drugs](https://elitepepsaustralia.com/amylin-vs-glp-1-obesity-drugs/): Understand how amylin and GLP-1 targets differ, what CagriSema combines, and what published cagrilintide, petrelintide and eloralintide trials show.
- [Oral GLP-1 Medicines: Approval and Clinical-Trial Evidence Tracker](https://elitepepsaustralia.com/oral-glp-1-weight-loss-drugs-evidence-tracker/): Compare FDA decisions and primary trial evidence for oral semaglutide and orforglipron, with dates, trial identifiers and clear limits on comparisons.
- [Mass Spectrometry vs Amino Acid Analysis: What Peptide Tests Show](https://elitepepsaustralia.com/mass-spectrometry-vs-amino-acid-analysis-peptides/): A primary-source comparison of mass spectrometry and amino acid analysis, separating peptide identity, sequence, composition and quantitative content.
- [What Is GLP-1? The Hormone, Receptor and Medicines Explained](https://elitepepsaustralia.com/what-is-glp-1-hormone-receptor-agonists/): A source-linked explanation of GLP-1 biology, the difference between a hormone and receptor agonist, and how to interpret single, dual and triple receptor claims.
- [Foundayo (Orforglipron): What the October 2026 EMA Opinion Means](https://elitepepsaustralia.com/foundayo-orforglipron-ema-opinion-october-2026/): On 15 October 2026, the European Medicines Agency's human medicines committee recommended marketing authorisation for Foundayo (orforglipron) for adult weight management and type 2 diabetes.
- [NSW Peptide Emergency-Department Presentations: What 1,180 Visits Show](https://elitepepsaustralia.com/nsw-peptide-emergency-department-presentations-2026/): NSW Health recorded 1,180 emergency-department presentations mentioning unapproved peptide use between 1 July 2025 and 30 September 2026.
- [Obesity Drug Clinical Trial Results Tracker (2026)](https://elitepepsaustralia.com/obesity-drug-clinical-trial-results-tracker-2026/): A continuously updated, source-linked tracker of major 2026 obesity-drug trial results, including retatrutide, CagriSema, survodutide and petrelintide.
- [Mounjaro and Eye Disorders in Australia: NAION Warning Explained (2026)](https://elitepepsaustralia.com/mounjaro-eye-disorder-naion-australia-tga-warning/): Australian evidence guide to Mounjaro, tirzepatide and NAION: what the TGA warning says, what 10 reports can and cannot establish, and why semaglutide evidence differs.
- [Ozempic vs Wegovy Australia (2026): TGA Approval and PBS Differences](https://elitepepsaustralia.com/ozempic-vs-wegovy-australia-2026-tga-approval-and-pbs-differences/): Short answer (checked 7 October 2026): Ozempic and Wegovy both contain semaglutide, but they are not the same Australian regulatory or PBS proposition.
- [Compounded GLP-1 Australia (2026): What the TGA Rules Actually Say](https://elitepepsaustralia.com/compounded-glp-1-australia-2026-what-the-tga-rules-actually-say/): Current Australian answer (checked 7 October 2026): Australian pharmacists must not compound medicines containing GLP-1 receptor agonist analogues.
- [GLP-1 Safety Warnings Australia (2026): TGA Updates Explained](https://elitepepsaustralia.com/glp-1-safety-warnings-australia-2026-tga-updates-explained/): Source-checked 7 October 2026: Australia’s TGA has updated warnings for GLP-1 receptor agonists and the dual GIP/GLP-1 medicine tirzepatide across several distinct issues: aspiration around general anaesthesia or deep sedation, potential suicidal thoughts, a Mounjaro oral-contraception interaction warning, and the rare eye disorder NAION.
- [Wegovy PBS Australia (2026): Is Semaglutide Listed Yet?](https://elitepepsaustralia.com/wegovy-pbs-australia-2026-is-semaglutide-listed-yet/): Current answer (checked 7 October 2026): Wegovy is TGA-approved in Australia for chronic weight management, and PBAC recommended a restricted PBS listing for a defined group with established cardiovascular disease and obesity.
- [Mounjaro PBS Australia 2026: Listing Status & Negotiations](https://elitepepsaustralia.com/mounjaro-pbs-australia-2026-tirzepatide-approval-subsidy-and-current-status/): Current answer — checked 8 October 2026: Mounjaro (tirzepatide) is TGA-approved in Australia for type 2 diabetes and chronic weight management, but it is not currently PBS-listed.
- [Peptide Lab Tests vs TGA Approval: What Each Proves in Australia](https://elitepepsaustralia.com/peptide-lab-test-tga-approval-australia/): A passing peptide lab result is not TGA approval. Learn how CoAs, HPLC, mass spectrometry, sterility, GMP, ARTG inclusion and lawful access differ in Australia.
- [TGA vs ARTG vs PBAC vs PBS: How Australian Medicine Approval and Subsidy Differ](https://elitepepsaustralia.com/tga-artg-pbac-pbs-differences/): A practical Australian guide to four commonly confused medicine-status questions: TGA assessment, ARTG inclusion, PBAC recommendations and PBS subsidy.
- [Mass Spectrometry vs HPLC for Peptide Testing](https://elitepepsaustralia.com/mass-spectrometry-vs-hplc-peptide-testing/): A practical guide to what HPLC, mass spectrometry and LC–MS can—and cannot—prove about peptide identity, purity, assay, impurities and safety claims.
- [How to Read a Weight-Loss Drug Trial: Endpoints, Dropouts, Safety and Comparisons](https://elitepepsaustralia.com/how-to-read-weight-loss-drug-clinical-trial/): An evidence-literacy guide to weight-loss drug trials: populations, endpoints, estimands, missing data, discontinuations, safety and cross-trial comparisons.
- [GLP-1 Medicines in Australia (2026): TGA Approval, PBS Access and Safety Updates](https://elitepepsaustralia.com/glp-1-medicines-australia-tga-pbs-status-2026/): A dated, source-linked guide to GLP-1 medicines in Australia: TGA-approved indications, PBS access, Wegovy’s listing status and 2026 safety updates.
- [TB-500 Australia: Schedule 4, Human Evidence, FDA Review and WADA Rules](https://elitepepsaustralia.com/tb-500-australia-schedule-4-evidence-fda-wada/): What TB-500 is, how it differs from full-length thymosin beta-4, what Australian Schedule 4 status means, and why human healing claims remain uncertain.
- [CJC-1295 and Ipamorelin: Evidence, FDA Safety Flags and 2026 WADA Status](https://elitepepsaustralia.com/cjc-1295-ipamorelin-evidence-fda-safety-wada-2026/): CJC-1295 and ipamorelin are often marketed together, but they are different growth-hormone-pathway substances with limited clinical evidence and distinct safety questions.
- [FDA Peptide Compounding Safety Review (2026): BPC-157, TB-500, MOTS-c, CJC-1295 and More](https://elitepepsaustralia.com/fda-peptide-compounding-safety-review-2026/): A substance-by-substance guide to the FDA's current peptide compounding safety concerns, including immunogenicity, aggregation, impurities and gaps in human exposure data.
- [TGA Peptide Enforcement 2026: What the Retatrutide, CJC-1295 and Wolverine Stack Case Shows](https://elitepepsaustralia.com/tga-peptide-enforcement-retatrutide-cjc-1295-wolverine-stack-2026/): The TGA's August 2026 enforcement action illustrates how importing, relabelling and social-media advertising create separate legal and safety risks around unapproved peptides.
- [Peptides and Sport: The 2026 WADA Prohibited List Explained](https://elitepepsaustralia.com/peptides-sport-2026-wada-prohibited-list-explained/): A plain-English map of the peptide-related substances prohibited in sport in 2026, including BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604 and MOTS-c.
- [BPC-157 Australia (2026): TGA Scheduling, Human Evidence, FDA Safety and WADA Status](https://elitepepsaustralia.com/bpc-157-australia-tga-human-evidence-wada-status/): A source-led guide to BPC-157 in Australia: what Schedule 4 means, what human evidence exists, why online healing claims run ahead of the data, and how FDA and WADA positions differ.
- [GLP-3 Australia: What the Term Means, Retatrutide Evidence and TGA Status](https://elitepepsaustralia.com/glp-3-australia-retatrutide-tga-status/): What “GLP-3 Australia” usually means, why the term is informal, how it maps to retatrutide’s three receptor targets, and the current TGA position.
- [Press Release vs Peer-Reviewed Paper: A Six-Question Evidence Check](https://elitepepsaustralia.com/press-release-vs-peer-reviewed-paper/): How to interpret topline trial announcements before the full protocol, tables and peer-reviewed paper are available.
- [CagriSema REIMAGINE 2: What the Published Phase 3 Trial Shows](https://elitepepsaustralia.com/cagrisema-reimagine-2-results-2026/): REIMAGINE 2 published results: HbA1c, safety and trial limits, with sponsor headlines compared against the peer-reviewed phase 3 paper.
- [Wegovy HD: What the FDA’s 7.2 mg Semaglutide Approval Means—and What It Does Not](https://elitepepsaustralia.com/wegovy-hd-fda-7-2-mg-semaglutide-approval-2026/): The FDA approved a higher-dose semaglutide injection in March 2026. Here is the regulatory fact pattern, safety context and Australian caveat.
- [How to Read an HPLC Chromatogram: Peaks, Area & Purity](https://elitepepsaustralia.com/how-to-read-hplc-chromatogram-peak-area-purity/): A practical HPLC chromatogram guide: retention time, peak area, baseline integration, system suitability and why area percent is not mass purity.
- [What Is a Peptide? Peptides vs Proteins, Hormones and Small Molecules](https://elitepepsaustralia.com/what-is-a-peptide-vs-protein-hormone-small-molecule/): A practical classification guide explaining why peptide, protein, hormone and small-molecule labels overlap—and why mechanism and evidence matter more than marketing.
- [Tirzepatide vs Semaglutide: What the SURMOUNT-5 Head-to-Head Trial Actually Shows](https://elitepepsaustralia.com/tirzepatide-vs-semaglutide-surmount-5-head-to-head-trial/): A careful reading of SURMOUNT-5: design, 72-week weight outcomes, waist outcomes, safety, funding and the limits of one open-label comparison.
- [FDA Warning on Unapproved GLP-1 Products and “Research Use Only” Marketing](https://elitepepsaustralia.com/fda-warning-unapproved-glp-1-research-use-only-products-2026/): The FDA’s September 2026 GLP-1 warning explains why unapproved, counterfeit and falsely labelled products cannot be treated as equivalents of approved medicines.
- [Phase 1, 2, 3 and 4 Trials: What Each Stage Can—and Cannot—Establish](https://elitepepsaustralia.com/clinical-trial-phases-what-they-mean/): Clinical-trial phases answer different questions. Learn why Phase 1 safety, Phase 2 signals, Phase 3 confirmation and Phase 4 monitoring should not be collapsed.
- [How to Read a Clinical Trial Registry Record Without Overclaiming](https://elitepepsaustralia.com/how-to-read-clinical-trial-registry-record/): A field-by-field guide to study status, design, outcomes, estimands, dates, enrolment and results on ClinicalTrials.gov and ANZCTR.
- [ARTG, Unapproved Therapeutic Goods and Clinical Trials: An Australian Reader’s Guide](https://elitepepsaustralia.com/artg-unapproved-therapeutic-goods-clinical-trials-australia/): How to distinguish ARTG inclusion, clinical-trial access, exemptions, overseas approval and online ‘research use only’ claims in Australia.
- [TGA Retatrutide Alert: Semaglutide Found in Tested Vial](https://elitepepsaustralia.com/tga-retatrutide-counterfeit-safety-alert-september-2026/): The TGA says a product sold as retatrutide contained undeclared semaglutide, no retatrutide, and was linked to a serious adverse event. What the 14 September 2026 alert establishes.
- [From Lyophilised Peptide to Solution: Stability Variables and Study Design](https://elitepepsaustralia.com/peptide-reconstitution-protocols/): A non-procedural guide to the factors that determine peptide stability after dissolution, including formulation, temperature, light, oxidation, adsorption, agitation and study design.
- [BPC-157 and TB-500 Together: Why “Synergy” Claims Exceed the Evidence](https://elitepepsaustralia.com/bpc-157-tb-500-healing/): A critical appraisal of combination claims: complementary mechanisms are a hypothesis, not proof of improved outcomes, safety, stability or compatibility.
- [Retatrutide Mechanism: What Triple GIP, GLP-1 and Glucagon Agonism Means](https://elitepepsaustralia.com/retatrutide-triple-agonist/): A receptor-by-receptor explanation of retatrutide, separating established human observations from preclinical mechanisms and popular oversimplifications.
- [Research Peptide Storage Records: Temperature Excursions, Light and Traceability](https://elitepepsaustralia.com/storage-basics-for-research-peptides/): A quality-system guide to documenting storage conditions and assessing temperature excursions without relying on generic peptide storage claims.
- [Independent Batch Testing: Sampling, Chain of Custody and Reproducibility](https://elitepepsaustralia.com/why-independent-batch-testing-matters/): Why an independent result is only as strong as the sample it represents, the custody record that connects it to a lot, and the method’s reproducibility.
- [How to Read a Peptide Certificate of Analysis: A Field-by-Field Guide](https://elitepepsaustralia.com/how-to-read-a-peptide-lab-report/): An Australia-focused guide to verifying a peptide certificate of analysis, spotting red flags and separating identity, HPLC area, assay, sterility and regulatory status.
- [Independent Laboratory Verification: What HPLC and Mass Spectrometry Can—and Cannot—Prove](https://elitepepsaustralia.com/australian-lab-verification/): A practical guide to reading peptide analytical reports: identity, purity, quantity, sterility, endotoxin, method validation and laboratory accreditation.
- [Bacteriostatic Water in Laboratory Research: Composition, Controls and Limitations](https://elitepepsaustralia.com/free-bac-water-every-order/): What bacteriostatic water is, how it differs from sterile preservative-free water, and which quality and compatibility questions a laboratory must control.
- [Retatrutide Trial Tracker: Phase 2 Evidence, Phase 3 Results and Regulatory Status](https://elitepepsaustralia.com/retatrutide-triple-agonist-explained/): Updated 6 October 2026: peer-reviewed TRIUMPH-1 Phase 3 results, estimand differences, the wider trial programme, safety findings and current Australian regulatory status.
- [BPC-157 vs TB-500: Evidence Quality, Biology and Research Gaps](https://elitepepsaustralia.com/bpc-157-vs-tb-500-research-comparison/): A source-led comparison that distinguishes BPC-157, thymosin beta-4 and TB-500, maps the human and preclinical evidence, and explains what remains unknown.
- [How Elite Peps Australia Evaluates Scientific Evidence](https://elitepepsaustralia.com/hello-world/): Our transparent editorial method for separating human evidence, clinical trials, preclinical research, laboratory findings and regulatory facts.

## Pages

- [Laboratory Research Tools](https://elitepepsaustralia.com/research-tools/): Free browser-based laboratory calculators for molarity, mass, dilution, serial dilution, half-life modelling and scientific unit conversion.
- [Privacy Policy](https://elitepepsaustralia.com/privacy-policy/): Elite Peps Australia respects reader privacy and aims to collect only the information reasonably required to operate and improve this publication.
- [Advertising & Monetisation Policy](https://elitepepsaustralia.com/advertising-policy/): Elite Peps Australia is being developed as an advertising-supported knowledge publication.
- [Corrections Policy](https://elitepepsaustralia.com/corrections-policy/): Scientific and regulatory information changes, and mistakes should be corrected clearly rather than quietly ignored.
- [Editorial Policy](https://elitepepsaustralia.com/editorial-policy/): Elite Peps Australia is a knowledge-only publication.
- [Laboratory Science](https://elitepepsaustralia.com/lab-science/): Analytical claims are only useful when readers understand what was measured.
- [Australia & TGA Regulation](https://elitepepsaustralia.com/australia-regulation/): Scientific interest, trial access, Australian medicine registration and PBS subsidy are different questions.
- [Clinical Trials](https://elitepepsaustralia.com/clinical-trials/): Use this four-guide sequence to move from a headline to the registered plan, the correct development stage and the full evidence.
- [Legacy Purchases & Reader Support](https://elitepepsaustralia.com/refund_returns/): No products are currently sold. This retained URL explains the publication’s open-access model and legacy support route.
- [Peptide Science News: Trials and TGA Alerts](https://elitepepsaustralia.com/news/): Verified peptide-science, clinical-trial and Australian regulatory developments, dated and linked to primary sources.
- [Peptide Research Library: Evidence and Australian Status](https://elitepepsaustralia.com/research/): Evidence-led peptide research library covering mechanisms, human evidence, clinical trials, Australian regulation and laboratory science.
- [Blog](https://elitepepsaustralia.com/blog/)
- [Access & Availability](https://elitepepsaustralia.com/shipping/): Elite Peps Australia is an open-access digital publication; no physical goods are shipped.
- [Peptide Analytical Testing: Methods, Validation & Limits](https://elitepepsaustralia.com/lab-testing/): How HPLC, LC–MS, reference standards and method validation contribute different pieces of analytical evidence.
- [Analytical Reports & Certificates of Analysis](https://elitepepsaustralia.com/lab-reports/): An evidence-led guide to certificates of analysis, HPLC, LC–MS, method suitability and reporting limits.
- [Knowledge Base FAQ](https://elitepepsaustralia.com/faq/): Answers about evidence labels, updates, sources, Australian regulation, corrections, profiles and calculators.
- [Contact Elite Peps Australia](https://elitepepsaustralia.com/contact/): For editorial questions, correction requests, source suggestions, privacy enquiries or general feedback, contact admin@elitepepsaustralia.com.
- [About Elite Peps Australia](https://elitepepsaustralia.com/about-us/): Elite Peps Australia is an independent Australian knowledge publication focused on peptide science, emerging therapeutics, clinical trials, laboratory methods and regulation.
- [Peptide Science, Clinical Trials & Australian Regulation](https://elitepepsaustralia.com/): Evidence-led peptide science, clinical-trial intelligence, laboratory methods and Australian TGA regulation—explained clearly with sources and context.
- [Open Access — No Reader Account Required](https://elitepepsaustralia.com/my-account/): Articles, profiles and tools are available without creating an account or signing in.
- [No Checkout Required](https://elitepepsaustralia.com/checkout/): The knowledge base is open access; no checkout or payment is required.
- [Research Library Access](https://elitepepsaustralia.com/cart/): Elite Peps Australia is freely accessible and does not operate a shopping cart.
- [Shop](https://elitepepsaustralia.com/shop/)

## Products

- [Retatrutide: Evidence, Phase 3 Trials & Australian Regulatory Status (2026)](https://elitepepsaustralia.com/product/retatrutide/): Evidence-led overview of retatrutide (LY3437943): mechanism, Phase 2 peer-reviewed data, 2026 Phase 3 topline results, safety signals and current Australian regulatory status.
- [5-Amino-1MQ Australia: NNMT Evidence, Human Trial Gaps and Safety](https://elitepepsaustralia.com/product/5-amino-1mq/): 5-Amino-1MQ reduced fat measures in mouse studies, not human trials. Learn what NNMT research shows, what remains unknown and the Australian context.
- [AOD-9604 Australia: Human Trials, TGA Status and WADA Rules](https://elitepepsaustralia.com/product/aod-9604/): Evidence-led AOD-9604 profile covering human weight-loss trials, Schedule 4 status in Australia, the 2026 WADA prohibition and research limitations.
- [Bacteriostatic Water: Composition, Quality Controls and Regulatory Context](https://elitepepsaustralia.com/product/bac-water/): An evidence profile for bacteriostatic water: benzyl-alcohol preservative, multi-dose labelling, sterility, endotoxin, container integrity and limitations.
- [BPC-157 + TB-500 Combination: Evidence Gaps, Compatibility and Study Design](https://elitepepsaustralia.com/product/bpc-157-tb-500/): A critical profile of the BPC-157/TB-500 combination: no established human synergy evidence, no automatic 1:1 rationale, and separate quality and safety requirements.
- [BPC-157: Preclinical Evidence, Human Research Gaps and Regulatory Questions](https://elitepepsaustralia.com/product/bpc-157/): An evidence-led BPC-157 profile covering proposed mechanisms, the dominance of animal studies, limited human evidence, unresolved safety and research standards.
- [TB-500 and Thymosin Beta-4: Identity, Evidence and Critical Differences](https://elitepepsaustralia.com/product/tb-500/): TB-500 is not interchangeable with full-length thymosin beta-4. This profile separates the molecules, current evidence, metabolism data and unresolved human safety questions.
- [CJC-1295 with DAC: Human Evidence & Australia (2026)](https://elitepepsaustralia.com/product/cjc-1295-dac/): CJC-1295 with DAC evidence guide: human GH and IGF-1 studies, with-DAC versus no-DAC terminology, Australian regulation and 2026 WADA status.
- [CJC-1295 No DAC + Ipamorelin: Terminology, Evidence and Safety Gaps](https://elitepepsaustralia.com/product/cjc-1295-no-dac-ipamorelin/): “CJC-1295 no DAC” is used inconsistently. Learn how it differs from long-acting CJC-1295, what combination evidence exists and what remains unknown.
- [DSIP Peptide: Human Sleep Studies, Evidence Gaps and Australia](https://elitepepsaustralia.com/product/dsip15mg/): DSIP was tested in small insomnia studies, but effects were weak and inconsistent. Review the human evidence, history, safety gaps and Australian context.
- [GHK-Cu Copper Peptide: Evidence, Human Studies & Australian Status (2026)](https://elitepepsaustralia.com/product/ghk-cu/): GHK-Cu evidence guide: human skin studies, topical-versus-injectable limits, copper-peptide quality claims and current Australian regulatory context.
- [GLOW Peptide Blend: GHK-Cu, BPC-157 and TB-500 Evidence Appraisal](https://elitepepsaustralia.com/product/glow/): The name GLOW describes a marketed mixture, not a clinically validated intervention. Review the component evidence, formulation unknowns and missing combination trials.
- [IGF-1 LR3: Experimental Analogue, Receptor Biology and Evidence Gaps](https://elitepepsaustralia.com/product/igf1-lr3/): An evidence-led profile of Long R3 IGF-1, an experimental IGF-1 analogue used in laboratory research, with emphasis on identity, model limitations and safety unknowns.
- [Kisspeptin Australia: Human Fertility Evidence, KISS1R and Research Limits](https://elitepepsaustralia.com/product/kisspeptin/): Kisspeptin can activate human reproductive hormone pathways, but it is not a general fertility treatment. Read the IVF evidence, limits and Australian status.
- [KLOW Peptide Blend: Component Evidence, Synergy Claims and Safety Gaps](https://elitepepsaustralia.com/product/klow/): KLOW is a commercial blend label, not a clinically validated therapy. Compare GHK-Cu, TB-500, BPC-157 and KPV evidence with mixture-specific unknowns.
- [Melanotan II Australia: TGA Status, Evidence and Safety Risks](https://elitepepsaustralia.com/product/mt-2/): Melanotan II is Schedule 4 and not ARTG-approved for tanning in Australia. Read the human evidence, mole and melanoma limits, safety risks and TGA advice.
- [MOTS-c Australia: Human Evidence, Exercise Studies and WADA Status](https://elitepepsaustralia.com/product/mots-c-10/): Evidence-led MOTS-c guide covering human exercise and biomarker studies, limits of animal research, Australian regulatory context and 2026 WADA status.
- [NAD+ Australia: Human Evidence, IV Infusions, NR, NMN and TGA Status](https://elitepepsaustralia.com/product/nad-plus/): NAD+ is essential biology, but raising a biomarker is not proof of anti-ageing benefit. Compare IV NAD+, NR and NMN evidence with current Australian TGA status.
- [PT-141 Australia: Bremelanotide Evidence, FDA Approval and Safety Limits](https://elitepepsaustralia.com/product/pt-141/): Evidence-led review of bremelanotide (PT-141): the narrow FDA indication, Phase 3 trial endpoints, safety warnings, Australian regulatory context and limits of online product claims.
- [Selank Australia: Human Evidence, GABA Claims and Research Gaps](https://elitepepsaustralia.com/product/selank/): Selank has preclinical GABA and gene-expression research, but modern human trials are limited. Review anxiety claims, evidence gaps and Australian status.
- [Semax: ACTH(4–10) Analogue, Neuroscience Evidence and Translation Limits](https://elitepepsaustralia.com/product/semax/): Semax is a synthetic ACTH-fragment analogue studied mainly in Russian neuroscience literature. Review proposed mechanisms, human-evidence limitations and regulatory questions.
- [SLU-PP-332: Mouse Evidence, “Exercise Mimetic” Claims and Human Gaps](https://elitepepsaustralia.com/product/slupp-332/): SLU-PP-332 is a preclinical small molecule, not a peptide or approved exercise pill. Review the mouse studies, 2026 research and missing human evidence.
- [SS-31 / Elamipretide: Forzinity Approval, Human Evidence and Australia](https://elitepepsaustralia.com/product/ss-31/): Forzinity has accelerated FDA approval for a narrow Barth-syndrome population. Learn what this means—and why it does not prove broad anti-ageing claims.
- [Tesamorelin Australia: Clinical Evidence, Uses & Regulatory Status](https://elitepepsaustralia.com/product/tesamorelin-10/): Tesamorelin evidence guide: HIV-lipodystrophy indication, visceral-fat trials, safety limits and how to verify current Australian regulatory status.
- [Tesamorelin: Approved HIV-Lipodystrophy Evidence and Limits of Extrapolation](https://elitepepsaustralia.com/product/tesamorelin-20/): Tesamorelin is a GHRH analogue with a specific prescription indication in the United States. Its evidence cannot be generalised to routine weight loss or anti-ageing use.
- [Ipamorelin Australia: Human Evidence, FDA Safety and 2026 WADA Status](https://elitepepsaustralia.com/product/ipamorelin/): Ipamorelin can release growth hormone, but wellness claims outrun the trials. Review human evidence, FDA concerns, Australian status and 2026 WADA rules.
- [Disposable Injection Pens: Device Engineering, Human Factors and Australian Regulation](https://elitepepsaustralia.com/product/disposable-pens/): An educational overview of disposable pen-injector design, dose accuracy, usability, container closure, sharps safety and medical-device regulation.
- [GLP3-RT and Retatrutide: Terminology, Evidence and Australian Safety Alert](https://elitepepsaustralia.com/product/glp3-rt-triple-agonist-research-peptide-australia/): GLP3-RT is an informal marketing label associated with retatrutide. The accurate description is a GIP, GLP-1 and glucagon triple agonist. Current evidence and TGA status.

## Optional

- [Agent (MCP protocol)](websites-agents.hostinger.com/elitepepsaustralia.com/mcp)

[comment]: # (Generated by Hostinger Tools Plugin)